FDA-cleared profile

CaRi-Plaque

Caristo Diagnostics Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: CaRi-Plaque is a web-based post-processing tool for trained operators and healthcare professionals that analyzes previously acquired CCTA DICOM data for coronary plaque characteristics, plaque burden, luminal stenosis, and related vessel measurements.

Clinical role
Post-processing and report generation for coronary plaque composition, burden, remodeling, and luminal stenosis assessment from an existing CCTA examination.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The service analyzes previously acquired CCTA rather than acquiring images. Caristo describes trained operators reviewing outputs before delivery, but plaque measurements and stenosis estimates remain adjunctive and require clinician review. FDA validation is regulatory and not independent clinical-outcome evidence.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: CaRi-Plaque is a web-based post-processing tool for trained operators and healthcare professionals that analyzes previously acquired CCTA DICOM data for coronary plaque characteristics, plaque burden, luminal stenosis, and related vessel measurements.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Previously acquired adult CCTA DICOM data sent through a secure PACS or local hard drive for processing.
  • Who uses it?Intended users: Trained internal operators and healthcare professionals reviewing adult CCTA-derived plaque analysis; the report supports but does not replace clinical judgment.
  • What does the software produce?Output: Maximum stenosis; total, calcified, non-calcified, and low-density non-calcified plaque volumes; plaque burden; remodeling index; vessel and lumen profiles; and a DICOM-conformant or PDF report for healthcare-professional review.
  • What is its most important limitation?Key limitation: The service analyzes previously acquired CCTA rather than acquiring images. Caristo describes trained operators reviewing outputs before delivery, but plaque measurements and stenosis estimates remain adjunctive and require clinician review. FDA validation is regulatory and not independent clinical-outcome evidence.

Clinical takeaway. Clinical role: CaRi-Plaque is a web-based post-processing tool for trained operators and healthcare professionals that analyzes previously acquired CCTA DICOM data for coronary plaque characteristics, plaque burden, luminal stenosis, and related vessel measurements.

Evidence takeaway. Evidence from the reviewed source record: K242240 FDA evidence is a four-site regulatory validation of CaRi-Plaque measurements from CCTA; no independent paper or trial was promoted in this timeboxed review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
CaRi-Plaque is a web-based post-processing tool for trained operators and healthcare professionals that analyzes previously acquired CCTA DICOM data for coronary plaque characteristics, plaque burden, luminal stenosis, and related vessel measurements.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Post-processing and report generation for coronary plaque composition, burden, remodeling, and luminal stenosis assessment from an existing CCTA examination.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Previously acquired adult CCTA DICOM data sent through a secure PACS or local hard drive for processing.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Maximum stenosis; total, calcified, non-calcified, and low-density non-calcified plaque volumes; plaque burden; remodeling index; vessel and lumen profiles; and a DICOM-conformant or PDF report for healthcare-professional review.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Cardiology or radiology workflow in which previously acquired CCTA is sent for coronary plaque analysis and returned for clinician review.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Trained internal operators and healthcare professionals reviewing adult CCTA-derived plaque analysis; the report supports but does not replace clinical judgment.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The service analyzes previously acquired CCTA rather than acquiring images. Caristo describes trained operators reviewing outputs before delivery, but plaque measurements and stenosis estimates remain adjunctive and require clinician review. FDA validation is regulatory and not independent clinical-outcome evidence.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K242240 FDA evidence is a four-site regulatory validation of CaRi-Plaque measurements from CCTA; no independent paper or trial was promoted in this timeboxed review.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K242240 FDA evidence is a four-site regulatory validation of CaRi-Plaque measurements from CCTA; no independent paper or trial was promoted in this timeboxed review.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Maximum stenosis Pearson correlation

0.93 Pearson correlation coefficient

  • EndpointAgreement of maximum stenosis measurement with reference
  • Population117 adult subjects from four sites
  • Tested versionCaRi-Plaque configuration described in K242240

Total plaque volume Pearson correlation

0.985 Pearson correlation coefficient

  • EndpointAgreement of total plaque volume with reference
  • Population117 adult subjects from four sites
  • Tested versionCaRi-Plaque configuration described in K242240

Calcified plaque volume Pearson correlation

0.999 Pearson correlation coefficient

  • EndpointAgreement of calcified plaque volume with reference
  • Population117 adult subjects from four sites
  • Tested versionCaRi-Plaque configuration described in K242240

Non-calcified plaque volume Pearson correlation

0.977 Pearson correlation coefficient

  • EndpointAgreement of non-calcified plaque volume with reference
  • Population117 adult subjects from four sites
  • Tested versionCaRi-Plaque configuration described in K242240

K242240 CaRi-Plaque regulatory validation

  • DesignRetrospective multi-site regulatory validation comparing CaRi-Plaque plaque and stenosis measurements with reference measurements.
  • Population117 subjects, 85 men and 32 women aged 27-85, from four sites including two U.S. and two outside the U.S.; CT scanners included Toshiba, GE, Philips, and Siemens.
  • Scopeexact submission
  • Tested versionCaRi-Plaque configuration described in K242240
  • Samplen=117
  • Sites4
  • IndependenceSponsor or vendor study

K242240

Manufacturer-submitted FDA evidence; it is not an independent clinical-outcome study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K242240. This does not establish absence of family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
CMS LCD L39913 v7 and Article A59813 v6 provide conditional service-level policy context for AI-QCT/AI-CPA after completed and interpreted CCTA in WPS Medicare J5/J8 for selected symptomatic chest-pain patients; exact product/version eligibility and individual claim eligibility are not established.
  • Product family
  • Checked 2026-09-07

Service-level policy context; exact product/version and individual claim eligibility are not established. This is not a product code assignment, universal Medicare coverage determination, fee, or price.

75577

Conditional service-level coverage; product eligibility unconfirmed

Medicare / WPS · United States - WPS J5/J8 jurisdictions · Effective 2026-01-01

CMS policy context applies to an eligible CCTA plaque-analysis service in a limited WPS policy scope; it does not assign coverage to K242240 or establish individual claim eligibility.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Previously acquired adult CCTA DICOM data sent through a secure PACS or local hard drive for processing.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K242240: CaRi-Plaque

  2. Routing

    Source context, not route validation: CCTA data can be transferred through secure PACS or local hard drive and the report can be delivered in DICOM-conformant or PDF form; local PACS/RIS routing, identifiers, report ingestion, and turnaround should be acceptance-tested.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K242240: CaRi-Plaque

  3. AI processing

    Source context, not route validation: The exact FDA packet and Caristo product page describe web-based processing in off-site or cloud data-center infrastructure with secure transfer and de-identification before processing; current hosting region, retention, availability, and service-level terms remain unestablished.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K242240: CaRi-Plaque · CaRi-Plaque coronary plaque analysis

  4. Returned objects

    Source context, not route validation: Maximum stenosis; total, calcified, non-calcified, and low-density non-calcified plaque volumes; plaque burden; remodeling index; vessel and lumen profiles; and a DICOM-conformant or PDF report for healthcare-professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K242240: CaRi-Plaque

  5. Viewer/worklist/report

    Unresolved route: Maximum stenosis; total, calcified, non-calcified, and low-density non-calcified plaque volumes; plaque burden; remodeling index; vessel and lumen profiles; and a DICOM-conformant or PDF report for healthcare-professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K242240: CaRi-Plaque

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA packet and Caristo product page describe web-based processing in off-site or cloud data-center infrastructure with secure transfer and de-identification before processing; current hosting region, retention, availability, and service-level terms remain unestablished.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
CCTA data can be transferred through secure PACS or local hard drive and the report can be delivered in DICOM-conformant or PDF form; local PACS/RIS routing, identifiers, report ingestion, and turnaround should be acceptance-tested.
  • Exact FDA submission
  • Checked 2026-09-07
Security
Caristo states that it de-identifies data before cloud processing and that trained internal operators review results; this public family statement is not a scoped security attestation for the K242240 deployment.
  • Product family
  • Checked 2026-09-07

Confirm exact deployed controls, encryption, identity and access management, audit, retention, incident response, hosting region, and data-processing terms.

Training
Trained internal operators review processing and healthcare professionals review the returned report; local clinical users need onboarding for CCTA eligibility, report interpretation, discrepancy escalation, and integration failure handling.
  • Exact FDA submission
  • Checked 2026-09-07
Monitoring
Monitor CCTA eligibility and transfer, processing turnaround, operator review, report completeness, DICOM/PDF delivery, discrepancies, reruns, data-transfer failures, downtime, updates, complaints, and recalls by exact K242240 release.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA and official product workflow; it is not a claimed vendor monitoring service.

Secure CCTA transfer and returned report

Caristo describes transfer of CCTA data through secure PACS or local hard drive, de-identification before cloud processing, internal operator review, and delivery of DICOM-conformant or PDF reports; validate local transfer, identifiers, turnaround, and report ingestion.

product family · checked 2026-09-07

Current CaRi-Plaque family page; confirm exact K242240 release, contract data boundary, and operating terms.

Cloud/off-site processing boundary

The reviewed exact FDA packet describes off-site regional data-center processing, while the current family page describes de-identification before cloud processing; confirm hosting region, retention, availability, and data-processing terms for deployment.

exact submission · checked 2026-09-07

Plaque report content

The official CaRi-Plaque page lists maximum stenosis, total/calcified/non-calcified/low-density plaque volumes, plaque burden, and remodeling outputs, allowing buyer acceptance criteria to be tied to the returned report.

product family · checked 2026-09-07

Current family report description; exact K242240 output formatting and workflow configuration require confirmation.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242240
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-02-20
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, payer policy, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or contract unit for the exact K242240 configuration was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

10 sources - 3 history items

Source ledger

  1. FDA 510(k) K242240: CaRi-Plaque

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. CaRi-Plaque model card (K242240)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. CaRi-Plaque coronary plaque analysis

    Caristo Diagnostics - Accessed 2026-09-07

    Scope: identity, productFamily, clinicalUse, implementationCapabilities, evidenceContext

  8. openFDA exact recall query for K242240

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

  9. CMS LCD L39913 version 7

    Centers for Medicare & Medicaid Services - Accessed 2026-09-07

    Scope: reimbursementPolicy

  10. CMS Article A59813 version 6

    Centers for Medicare & Medicaid Services - Accessed 2026-09-07

    Scope: reimbursementPolicy

Research history

  1. K242240 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K251656

Careverse CoronaryDoc (Careverse CoronaryDoc)

Careverse Technology Pte. Ltd.

Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-09-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history